Empire Genomics and BioDot Collaborate to Enhance Hematology Diagnostics with Innovative Probe Panels

Empire Genomics and BioDot: A Groundbreaking Partnership in Hematology Diagnostics

Empire Genomics, a prominent player in molecular diagnostics and a Biocare Medical company, has announced an exciting new partnership with BioDot, a leader in precision dispensing automation. This collaboration aims to revolutionize FISH (Fluorescence In Situ Hybridization) testing for hematologic malignancies, particularly through the introduction of the BDot Probe Line, which is optimized for use on the BioDot CellWriter™ S platform.

The Need for Optimization in FISH Probes

In the increasingly complex world of clinical cytogenetics and molecular pathology, there is a pressing need for optimized protocols that ensure the compatibility of various FISH probes with automated systems. Traditionally, lab technicians have had to spend significant amounts of time troubleshooting and optimizing these probes, a process that not only consumes precious resources but also delays critical results.

The newly launched BDot Probe Line is groundbreaking because it is the first commercially available FISH probe reagent line that is fully pre-optimized and ready for immediate use on the CellWriter S system. By eliminating the optimization steps traditionally associated with FISH testing, this innovative solution considerably reduces the turnaround time for results, enabling labs to streamline their workflow dramatically.

Targeting Hematologic Malignancies

The initial offering within the BDot Probe Panels includes targeted solutions for a wide array of hematologic malignancies ranging from Multiple Myeloma (MM) and Myelodysplastic Syndromes (MDS) to Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), and Acute Lymphoblastic Leukemia (ALL). These panels are designed to provide exceptionally high performance, which allows for accurate diagnosis and timely intervention in patient care.

To accompany these panels, a control probe line has also been co-developed. This proprietary product is specifically optimized for the CellWriter S, enabling laboratories to easily verify and standardize their performance, thereby promoting consistent and reliable results across different testing environments.

Quotes from Industry Leaders

John Steel, Senior Vice President of Empire Genomics, expressed excitement at the collaboration, stating, "We’re thrilled to partner with BioDot to deliver a turnkey hematology FISH solution, combining the precision of Empire Genomics' probes with an automation platform designed to conserve valuable reagents." This partnership not only promises faster results but also enhances the reliability of laboratory output, ensuring that data accuracy is maintained throughout the testing process.

BioDot's General Manager, Debbie Bowers, emphasized the long-term vision of this partnership, noting, "This launch marks the first phase of a broader strategic partnership between BioDot and Biocare Medical. Together, we're committed to pushing the boundaries of FISH automation."

Early Success and Future Endeavors

Early adopters of the BDot Probe Panels have already reported impressive outcomes, highlighting exceptional signal quality and a significant reduction in hands-on time required for FISH testing. The implementation of this innovative technology aligns perfectly with the recent FDA regulations surrounding Laboratory-Developed Tests (LDTs), emphasizing the importance of validated and standardized diagnostic solutions.

As Empire Genomics and BioDot continue their collaboration, they have plans to expand the BDot product line further. More disease-specific panels and advanced tools for workflow automation, traceability, and reporting are set to be developed, paving the way for a new era in FISH diagnostics.

For those keen on staying updated with the advancements in hematology diagnostics, more information about the Empire Genomics BDot Probe Panels and the BioDot CellWriter S can be found on their respective websites: Empire Genomics and BioDot.

This impressive collaboration between two industry powerhouses is set to redefine standards in molecular diagnostics, ultimately benefiting both healthcare providers and patients alike.